Market revenue in 2022 | USD 16.3 million |
Market revenue in 2030 | USD 42.1 million |
Growth rate | 12.6% (CAGR from 2022 to 2030) |
Largest segment | Cholinesterase inhibitors |
Fastest growing segment | Combination Drugs |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drugs |
Key market players worldwide | Eisai Co Ltd, Novartis AG ADR, AbbVie Inc, H. Lundbeck AS Class A, Biogen Inc, Roche Holding AG ADR, Daiichi Sankyo Co Ltd, Johnson & Johnson, AC Immune SA |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to alzheimers therapeutics market will help companies and investors design strategic landscapes.
Cholinesterase inhibitors was the largest segment with a revenue share of 52.76% in 2022. Horizon Databook has segmented the Saudi Arabia alzheimers therapeutics market based on cholinesterase inhibitors, nmda receptor antagonist, combination drugs covering the revenue growth of each sub-segment from 2018 to 2030.
Increase in per capita healthcare expenditure and life expectancy in Saudi Arabia is expected to drive the Alzheimer’s therapeutics market in the coming years. According to Saudi Health Ministry, there were approximately 130 thousand people living with AD in the country in 2021.
Despite the high number of these patients, awareness about Alzheimer’s is relatively low. However, organizations like the Saudi Alzheimer’s Disease Association play a pivotal role in boosting AD awareness in the country.
The Ministry of Health and Saudi Alzheimer’s Association is focused on increasing awareness about the disease among patients and caregivers. The activities of these bodies include promotion of the services being extended to the patients and reduction in the risks of developing the condition by promotion of a healthy lifestyle.
Horizon Databook provides a detailed overview of country-level data and insights on the Saudi Arabia alzheimers therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Saudi Arabia alzheimers therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account